Recombinant Rat IL-6
- -
- -
BackgroundIL-6 is a pleotropic 26 kD protein that can act as both a pro-inflammatory cytokine and an anti-inflammatory myokine, a form of cytokine produced in muscle cells that participates in tissue regeneration and repair, maintenance of healthy bodily functioning, and homeostasis within the immune system. IL-6 plays a part in the immune, endocrine, nervous, and hematopoietic systems, in addition to bone metabolism, regulation of blood pressure and inflammation. Osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine. Furthermore, IL-6 is an important mediator of fever and of the acute phase response which is the body's rapid attempt to restore homeostasis after tissue injury, infection, neoplastic growth, or immunological disturbance. In addition, IL-6 can be released into circulation in response to various stimuli including PAMPs (pathogen-associated molecular patterns) and cortisol, a hormone produced by the human body under psychologically stressful conditions. In its role as an anti-inflammatory myokine, IL-6 precedes the appearance of other cytokines in the circulation, is notably elevated with exercise, and is mediated by both its inhibitory effects on TNF-α and IL-1, and activation of IL-1ra and IL-10. IL-6 signals through a cell-surface type I cytokine receptor complex formed by the binding of IL-6 to IL-6R, forming a binary complex, which in turn combines with GP130 to transduce extracellular signaling by the activation STAT3. Hence, it is thought that blocking the interaction between IL-6 and GP130 may have therapeutic potential via the inhibition of the IL-6/GP130/STAT3 signaling pathway. Moreover, IL-6 initiates the inflammatory and auto-immune processes in many diseases such as diabetes, atherosclerosis, depression, Alzheimer's disease, rheumatoid arthritis, cancer, and various others. Thus, there is an interest in the therapeutic potential of anti-IL-6 mAbs. Protein DetailsPurity >97% by SDS-PAGE and analyzed by silver stain. Endotoxin Level <0.01 EU/µg as determined by the LAL method Protein Accession No. Amino Acid Sequence mfptsqvrrg dftedtthnr pvyttsqvgg lityvlreil emrkelcngn sdcmnsddal sennlklpei qrndgcfqtg ynqeicllki csgllefrfy lefvknnlqd nkkdkarviq sntetlvhif kqeikdsyki vlptptsnal lmeklesqke wlrtktiqli lkaleeflkv tmrstrqt
N-terminal Sequence Analysis Met State of Matter Solution Predicted Molecular Mass The predicted molecular weight of Recombinant Rat IL-6 is Mr 22 kDa. Predicted Molecular Mass 22 Formulation This recombinant protein was 0.2 µm filtered and is supplied in a solution of 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA). Storage and Stability This recombinant protein can be stored at 2° to 8°C as supplied for six months. Do not freeze. Country of Origin USA Shipping Polar Packs NCBI Gene Bank References & Citations1. Pederson, BK. et al. (2005) Exerc Sport Sci Rev 33: 114 2. Baier, M. et al. (1997) Proceedings of the National Academy of Sciences (USA) 94: 5273 Certificate of AnalysisIMPORTANT Use lot specific datasheet for all technical information pertaining to this recombinant protein. |
Related Products
- -
- -
Prod No. | Description |
---|---|
I-633 | |
I-674 | |
I-1046 | |
I-1052 | |
I-1051 | |
I-213 | |
I-150 | |
I-165 | |
I-170 | |
I-208 | |
I-255 | |
I-256 | |
I-257 | |
I-188 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.